LabVantage Solutions has announced the availability of its new purpose-built COVID-19 LIMS solution, which is designed to jump-start the ability of laboratories to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research. The LabVantage COVID-19 Biobanking Accelerator is built on the company’s LIMS and Biobanking platforms.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. The solution is pre-configured to shorten implementation time, with a go-live start possible in less than four weeks. The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.